View Older Stories

Sep 30, 2026 05:43AM Jefferies Reiterates Buy Rating on Dyne Therapeutics (DYN)

Sep 29, 2026 09:25AM Piper Sandler Reiterates Overweight Rating on Dyne Therapeutics (DYN)

Sep 9, 2026 07:53AM Dyne Therapeutics (DYN) PT Lowered to $30 at RBC Capital Following NVS Setback

Sep 9, 2026 05:34AM Increasing unusual option volume: DYN GPRO KC DK ATAI PS FISV DPRO UGA TTAN REI CHPT BRZE

Sep 8, 2026 04:26PM JPMorgan Downgrades Dyne Therapeutics (DYN) to Underweight

Sep 8, 2026 10:39AM Dyne Therapeutics (DYN) PT Lowered to $37 at Raymond James

Sep 8, 2026 05:38AM Stifel on Dyne Therapeutics Inc. (DYN): 'we'd be buyers on weakness'

Aug 17, 2026 06:42AM H.C. Wainwright Reiterates Buy Rating on Dyne Therapeutics (DYN)

Jul 29, 2026 05:49PM Dynegy (DYN) Misses Q2 EPS by 33c

Jul 28, 2026 07:32AM FDA clears Dyne Therapeutics IND for DYNE-302 in rare muscle disease

Jul 23, 2026 07:35AM Cantor Fitzgerald Starts Dyne Therapeutics (DYN) at Overweight

Jul 20, 2026 11:29AM Dyne Therapeutics (DYN) PT Raised to $47 at Piper Sandler

Jul 20, 2026 07:30AM FDA accepts Dyne Therapeutics BLA for DMD drug z-rostudirsen

Jul 13, 2026 02:32PM Dyne Therapeutics Inc. (DYN) call put ratio 1.1 calls to 1 put as share price down 1.5%

Jun 26, 2026 05:53AM TD Cowen Starts Dyne Therapeutics (DYN) at Buy

Jun 17, 2026 07:30AM Dyne Therapeutics expands debt facility to $400M with Hercules Capital

May 26, 2026 07:31AM Dyne Therapeutics submits FDA application for DMD treatment

May 11, 2026 07:53AM Dynegy (DYN) Tops Q1 EPS by 4c

Apr 21, 2026 06:37AM H.C. Wainwright Reiterates Buy Rating on Dyne Therapeutics (DYN)

Apr 13, 2026 05:52AM Bernstein on US Pharma and Biotech: Who might buy whom?

Mar 25, 2026 03:21PM Raymond James Reiterates Strong Buy Rating on Dyne Therapeutics (DYN)

Mar 18, 2026 09:21AM RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'

Mar 9, 2026 12:34PM Baird on Dyne Therapeutics (DYN): 'Positive on clinical progress and improved regulatory dynamic'

Mar 9, 2026 11:55AM Jones Trading Reiterates Buy Rating on Dyne Therapeutics (DYN): "should clinch accelerated approval in the US"

Mar 9, 2026 11:45AM Stifel Reiterates Buy Rating on Dyne Therapeutics (DYN) following 2026 MDA conference

Mar 9, 2026 11:06AM Jones on Dyne Amid 14pct Gain: 'MDA'26: Best-in-Class DMD Program Looks Even Better'

Mar 9, 2026 10:29AM Stifel on Dyne Therapeutics Inc. (DYN): 'Longer-term Data At MDA Support DYNE-251's Strong DMD Profile'

Mar 9, 2026 09:22AM Jefferies on Dyne Therapeutics (DYN): 'We remain 70-80%+ confident in an AA approval by Q1:27'

Mar 9, 2026 05:26AM Dyne reports heart and lung function improvements in DMD trial

Mar 3, 2026 07:22AM Dyne Therapeutics (DYN) PT Lowered to $50 at H.C. Wainwright

Mar 2, 2026 05:37PM Chardan Reiterates Buy Rating on Dyne Therapeutics (DYN)

Mar 2, 2026 02:37PM Raymond James Reiterates Strong Buy Rating on Dyne Therapeutics (DYN)

Mar 2, 2026 11:12AM Dyne Therapeutics (DYN) PT Lowered to $47 at Morgan Stanley

Mar 2, 2026 08:39AM Dynegy (DYN) Tops Q4 EPS by 1c

Jan 20, 2026 07:30AM Dyne Therapeutics receives orphan drug designation in Japan for DM1 treatment

Dec 10, 2025 06:54AM Oppenheimer Upgrades Dyne Therapeutics (DYN) to Outperform

Dec 9, 2025 07:40AM Dyne Therapeutics (DYN) PT Raised to $23 at Bernstein SocGen Group

Dec 8, 2025 04:57PM After-hours movers: NVIDIA, Toll Brothers, and more

Dec 8, 2025 12:06PM Dyne Therapeutics (DYN) PT Raised to $50 at Morgan Stanley

Dec 8, 2025 09:27AM Dyne Therapeutics (DYN) PT Raised to $60 at H.C. Wainwright

Dec 8, 2025 09:26AM Baird Reiterates Outperform Rating on Dyne Therapeutics (DYN)

Dec 8, 2025 07:40AM Dyne Therapeutics (DYN) PT Raised to $40 at Raymond James

Nov 27, 2025 02:00AM Bernstein sees favorable risk-reward in this biotech stock

Nov 25, 2025 07:30AM Dyne Therapeutics (DYN) PT Raised to $21 at Bernstein SocGen Group, we see risk-reward as favorable

Nov 16, 2025 03:00PM Where can biotech stocks go from here? RBC answers

Nov 5, 2025 05:56PM Dynegy (DYN) Tops Q3 EPS by 8c

Oct 24, 2025 08:29AM Piper Sandler: 'Biotech Has a Heartbeat: 17 Stocks to Own Through YE25'

Oct 10, 2025 06:04AM Oppenheimer Downgrades Dyne Therapeutics (DYN) to Perform

Sep 29, 2025 08:35AM Dyne Therapeutics gets orphan drug status in Japan for DMD therapy

Sep 29, 2025 07:57AM Piper Sandler: 'Own Dyne Therapeutics (DYN) for DELIVER Data in Late 2025'

View Older Stories